Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.96 |
| ▸ | LTA4H | P09960 | 1/20 | 0.74 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.71 |
| ▸ | CCR3 | P51677 | 2/20 | 0.71 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.71 |
| ▸ | HRH1 | P35367 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10601122 | 1.00 | SIGMAR1 (0.96) | SIGMAR1LTA4HHRH3SLC6A3CCR3 | |
| SCHEMBL492561 | 0.98 | SIGMAR1 (1.00) | SIGMAR1LTA4HHRH3SLC6A3CCR3 | |
| SCHEMBL8091557 | 0.98 | SIGMAR1 (1.00) | SIGMAR1LTA4HHRH3SLC6A3CCR3 | |
| SCHEMBL8935099 | 0.98 | SIGMAR1 (0.96) | SIGMAR1LTA4HHRH3SLC6A3CCR3 | |
| Hydrochloric Acid SCHEMBL11555128 | 0.96 | SIGMAR1 (0.96) | SIGMAR1LTA4HHRH3SLC6A3CCR3 | |
| SCHEMBL7366514 | 0.96 | SIGMAR1 (1.00) | SIGMAR1LTA4HHRH3SLC6A3CCR3 | |
| SCHEMBL83687 | 0.94 | SIGMAR1 (0.86) | SIGMAR1LTA4HHRH3SLC6A3CCR3 | |
| SCHEMBL28881215 | 0.92 | SIGMAR1 (0.93) | SIGMAR1LTA4HSLC6A3CCR3GRIN2B | |
| Ammonia Solution, Strong SCHEMBL28704893 | 0.92 | SIGMAR1 (0.83) | SIGMAR1LTA4HHRH3SLC6A3CCR3 | |
| Hydrochloric Acid SCHEMBL8037018 | 0.92 | SIGMAR1 (0.83) | SIGMAR1LTA4HHRH3SLC6A3GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150231126-A1 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | ACADIA PHARM INC (US) | 2015-08-20 | — | — | US | claimed |
| US-20100129473-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | claimed |
| EP-2134330-A2 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | Acadia Pharmaceuticals Inc. (US) | 2009-12-23 | — | — | EP | claimed |
| EP-2088147-A1 | Dibenzo-condensed azepine, diazepine, oxazepine and thiazepine derivatives as muscarinic agonists and methods of treatment of neuropsychiatric disorders | Arcadia Pharmaceuticals Inc. (US) | 2009-08-12 | — | — | EP | claimed |
| EP-1696931-B1 | AMINO SUBSTITUTED DIARYL[A,D]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARM INC (US) | 2009-03-25 | — | — | EP | claimed |
| US-20090053329-A1 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | claimed |
| WO-2008118141-A2 | USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY | ACADIA PHARMACEUTICALS INC. (US) | 2008-10-02 | — | — | WO | claimed |
| WO-2008116024-A2 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | ACADIA PHARMACEUTICALS INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-20230406851-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-12-21 | — | — | US | disclosed |
| CN-116472042-A | 2-oxo-dihydroquinoline-3-carboxamide derivatives as modulators of GABA A type receptors | 加的夫大学学院咨询有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230149396-A1 | ORAL SOLID PREPARATIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230121578-A1 | SMALL MOLECULE MODULATORS OF THE BTB DOMAIN OF KEAP1 | SELVITA SERVICES SP. Z O.O. (PL) | 2023-04-20 | — | — | US | disclosed |
| CN-115666526-A | Oral solid preparation | 武田药品工业株式会社 | 2023-01-31 | — | — | CN | disclosed |
| EP-4114361-A1 | ORAL SOLID PREPARATIONS | Takeda Pharmaceutical Company Limited (JP) | 2023-01-11 | — | — | EP | disclosed |
| EP-0405436-A2 | Dihetero nitrogen-containing cycloheteroethanoanthracene derivatives as antipsychotic agents | G.D. Searle & Co. (US) | 1991-01-02 | — | — | EP | disclosed |
| EP-0164706-B1 | PHENYLALKYL AMINE BIOREGULATORS | BASF Aktiengesellschaft (DE) | 1989-04-05 | — | — | EP | disclosed |
| US-4395410-A | Quaternary ammonium antiarrhythmic drugs | ELI LILLY AND COMPANY (US) | 1983-07-26 | — | — | US | disclosed |
| EP-0002604-B1 | QUATERNARY AMMONIUM SALTS, AND THEIR FORMULATIONS AND PREPARATION | ELI LILLY AND COMPANY (US) | 1983-05-04 | — | — | EP | disclosed |
| US-4289787-A | PROLONG ACTION POTENTIAL OF CARDIAC TISSUE | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| EP-0002604-A1 | Quaternary ammonium salts, and their formulations and preparation | ELI LILLY AND COMPANY (US) | 1979-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129473-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CHRM4, CHRM5, CHRM1 | SIGMAR1 190/4885LTA4H 1121/4885HRH3 541/4885 |
| US-20150231126-A1 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | HTR2A, HTR3A, HTR1A | SIGMAR1 314/4885LTA4H 2639/4885HRH3 1015/4885 |
| US-20230406851-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | SIGMAR1 2026/4885LTA4H 2010/4885HRH3 213/4885 |
| US-20230121578-A1 | SMALL MOLECULE MODULATORS OF THE BTB DOMAIN OF KEAP1 | KEAP1, LRRK2, TFEB | SIGMAR1 3827/4885LTA4H 936/4885HRH3 640/4885 |
| US-20230149396-A1 | ORAL SOLID PREPARATIONS | DAO, DDO, XDH | SIGMAR1 2892/4885LTA4H 229/4885HRH3 222/4885 |
| US-20090053329-A1 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | HTR2A, HTR3A, HTR1A | SIGMAR1 287/4885LTA4H 2826/4885HRH3 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.